Newsroom | 5517 results

Sorted by: Latest

Optical
-

Drug Farm to Present Positive Phase 1b Data for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™

ALBANY, N.Y. & SHANGHAI--(BUSINESS WIRE)--Drug Farm today announced that preliminary immunologic and clinical results from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, will be presented in a podium session at IMMUNOLOGY2026, taking place April 15–19, 2026, in Boston, Massachusetts. The presentation will highlight early evidence of clinical benefit and pharmacodynamic improvement in patients with ROSAH syndrome, a rare genetic autoinflammatory disease driven by disease-ca...
-

Warby Parker to Announce First Quarter 2026 Financial Results on May 7, 2026

NEW YORK--(BUSINESS WIRE)--Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the first quarter ended March 31, 2026, will be released before market open on May 7, 2026. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing (833) 461-5787 from the U.S. or (5...
-

Glaukos Announces the Release of its 2025 Sustainability Report

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that it has published its 2025 Sustainability Report. The report highlights the company’s continued commitment and progress on its key corporate sustainability priorities. The Sustainability Report can be found on the company’s website here. “I am prou...
-

Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its one-of-a-kind ONE by ONE Recycling program, created in collaboration with international recycling leader TerraCycle®, has collected and recycled a total of 119,715,074 units, or 724,922 pounds, of used contact lenses, eye care and lens care materials in the United States – the equivalent of about five backya...
-

Glaukos Receives Permanent J-code for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa™ HD / Epioxa™ (“Epioxa”) for the treatment of keratoconus, a rare, sight-threatening disease...
-

Atia Vision Announces Durable 36-Month Results from First-in-Human Study of their Dynamic Shape-Changing OmniVu Intraocular Lens System

CAMPBELL, Calif.--(BUSINESS WIRE)--Atia Vision Announces Durable 36-Month Results from First-in-Human Study of their Dynamic Shape-Changing OmniVu Intraocular Lens System...
-

4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program

NEWTON, Mass.--(BUSINESS WIRE)--4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program...
-

Lineage Announces Formation of Scientific Advisory Board

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the formation of a Scientific Advisory Board (SAB) to provide strategic counsel and insights into the development of Lineage’s novel cell transplant pipeline, built on the Company’s proprietary cell differentiation and expansion platform, AlloSCOPE™...
-

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson showcases new clinical data for TECNIS PureSee IOL demonstrating excellent contrast sensitivity and extended range of vision...
-

STAAR Surgical Announces Preliminary Net Sales for First Quarter 2026

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales for the first quarter ended April 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement because it expects to be interacting with members of the investment community, as well as with surgeons and other members of t...